These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 20863169

  • 1. BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.
    Jönsson S, Olsson B, Jacobsson S, Palmqvist L, Ricksten A, Ekeland-Sjöberg K, Wadenvik H.
    Scand J Clin Lab Invest; 2011 Feb; 71(1):7-11. PubMed ID: 20863169
    [Abstract] [Full Text] [Related]

  • 2. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Feb; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 3. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
    Ballestrero A, Cirmena G, Dominietto A, Garuti A, Rocco I, Cea M, Moran E, Nencioni A, Miglino M, Raiola AM, Bacigalupo A, Patrone F.
    Int J Lab Hematol; 2010 Aug 01; 32(4):387-91. PubMed ID: 19968720
    [Abstract] [Full Text] [Related]

  • 4. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W, Gu BW, Zhu YM, Jiang CL, Zhao RH, Wang AH, Sun HP, Li JM, Shen ZX, Chen Z, Chen SJ.
    Zhonghua Yi Xue Za Zhi; 2005 Feb 23; 85(7):453-7. PubMed ID: 15854550
    [Abstract] [Full Text] [Related]

  • 5. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P, Kumar L, Mohanty S, Kochupillai V.
    Ann Hematol; 2010 Mar 23; 89(3):241-7. PubMed ID: 19714331
    [Abstract] [Full Text] [Related]

  • 6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 7. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR, Rempfer CB, Press RD.
    Methods Mol Biol; 2013 Oct 09; 999():1-23. PubMed ID: 23666687
    [Abstract] [Full Text] [Related]

  • 8. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 09; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2010 May 09; 199(1):56-61. PubMed ID: 20417871
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swale B, Milojkovic D, Reid A, Goldman J, Marin D.
    Am J Hematol; 2009 Aug 09; 84(8):517-22. PubMed ID: 19544476
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599
    [Abstract] [Full Text] [Related]

  • 17. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 18. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
    Sadia H, Siddiqui RT, Nasim A.
    Cancer Genet Cytogenet; 2010 Aug 05; 201(1):57-61. PubMed ID: 20633771
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
    Martinelli G, Testoni N, Montefusco V, Amabile M, Saglio G, Ottaviani E, Terragna C, Bonifazzi F, de Vivo A, Pane F, Rosti G, Tura S.
    Haematologica; 1998 Jul 05; 83(7):593-601. PubMed ID: 9718863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.